3 results
In this study we want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by the EGFR tyrosine kinase inhibitor erlotinb and metformin, combined with gemcitabine in patients with metatastatic pancreatic…
The study will be performed in 2 parts, Parts 1 and 2. The volunteers can only participate in one of the two parts of this study. The purpose of Part 1 of the study is to investigate to what extent RO6806127 is tolerated. It will also be…
To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.